After the No.44 document being issued in 2015，an unprecedented reform based on innovation spread across the pharmaceutical industry in China.On one hand，170000 marketed drugs on the market are undergoing the consistency evaluation；on the other hand，the adoption of MAH（Marketing Authorization Holder） unties the bond between drug approvals and drug manufacturing enterprises，keeps new drug manufacturing enterprises from entering the market，and improves the utilization rate of the industry's capacity.